February Freeze: Healthcare M&A Cools
Following a robust start in January, healthcare M&A volume declined notably in February. With 144 announced transactions, the deal volume for February 2026 is 40% lower than the 240 reported in January 2026, but marks a small decrease from the 150 announced in February 2025. Despite the decline in M&A volume, it is worth noting that February is historically a quiet month for deal activity and is following the trend; over the last five years, there has been an average of 150 deals reported throughout February. As with most months, most transactions were in the Physician Medical Group (PMG) sector, with 33 deals, accounting for 23% of activity. This is a 42% drop from the 57 PMG... Read More »
Beyond the Deal Volume: A Conversation With CEO Doug Drew of USOSM
Driven by a highly fragmented market landscape and sustained patient demand for care, the dental industry has emerged as an appealing sector for strategic consolidation and acquisition opportunities in the past five years. According to data captured in the LevinPro HC M&A database, the dental industry represents 48% of the Physician Medical Group sector’s activity, with 219 transactions announced since the start of 2025. Formed in 2017 and backed by Oak Hill Capital Partners, U.S. Oral Surgery Management (USOSM) has crafted a reputation as a dominating force in the dental space. With a presence in more than 30 states, USOSM provides operational, financial and administrative support... Read More »
October Deal Volume Dips 17% as Market Pressures Mount
The last few months have been a relentless storm of reimbursement and market changes. Far from finding calm, October has seen new challenges that have that power to impact healthcare M&A and deal activity. With substantial economic and regulatory pressures, healthcare M&A activity in October declined, but remained steady overall. According to data captured in the LevinPro HC database on November 3, preliminary numbers indicate that there was a 17% drop in deal volume from September (195 transactions) to October 2025 (162 transactions). It is worth noting that September 2025’s high deal activity is more of an outlier; October’s activity was more consistent with the... Read More »
AI, Pharma Services and Tariffs: The Healthcare Outlook from HPE New York
In mid-October, McDermott Will & Schulte’s Healthcare Private Equity New York conference brought healthcare leaders together to analyze the key challenges and trends shaping the industry in 2025. For one busy day, attendees heard from a series of panels that guided them through the complexities of private equity in healthcare and highlighted the most compelling investment sectors. It should be noted that media at the conference were bound by the Chatham House Rule, so we will refer to panelists anonymously unless we have received direct permission to use their names. “The boom days are back,” one panelist declared, echoing the enthusiasm at the conference around the... Read More »
Inside the 2025 Clinical Trials M&A Market
The clinical trials market, part of our newly formed Life Sciences R&D sector, has seen a shift in M&A deal volume over the last few years. The post-pandemic dealmaking frenzy has cooled, with acquirers now making more strategic and deliberate moves over the large-scale expansion of previous years. According to data captured in the LevinPro HC database, deal volume was modest before the post-pandemic surge, with 12 deals in 2019, 14 in 2020 and 18 in 2021. Volume escalated more than 66% in 2022 when 30 deals were reported. It hit a high in 2023 when 43 acquisitions were announced. However, M&A activity fell 37% in 2024 with 27 deals. If activity continues at its current pace,... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
